{"pre_text": ["abiomed , inc .", "and subsidiaries notes to consolidated financial statements 2014 ( continued ) note 14 .", "income taxes ( continued ) and transition and defines the criteria that must be met for the benefits of a tax position to be recognized .", "as a result of its adoption of fin no .", "48 , the company has recorded the cumulative effect of the change in accounting principle of $ 0.3 million as a decrease to opening retained earnings and an increase to other long-term liabilities as of april 1 , 2007 .", "this adjustment relates to state nexus for failure to file tax returns in various states for the years ended march 31 , 2003 , 2004 , and 2005 .", "the company has initiated a voluntary disclosure plan .", "the company has elected to recognize interest and/or penalties related to income tax matters in income tax expense in its consolidated statements of operations .", "as of april 1 , 2007 , accrued interest was not significant and was recorded as part of the $ 0.3 million adjustment to the opening balance of retained earnings .", "as of march 31 , 2008 , no penalties have been accrued which is consistent with the company 2019s discussions with states in connection with the company 2019s voluntary disclosure plan .", "on a quarterly basis , the company accrues for the effects of uncertain tax positions and the related potential penalties and interest .", "the company has recorded a liability for unrecognized tax benefits in other liabilities including accrued interest , of $ 0.2 million at march 31 , 2008 .", "it is reasonably possible that the amount of the unrecognized tax benefit with respect to certain of the unrecognized tax positions will increase or decrease during the next 12 months ; however , it is not expected that the change will have a significant effect on the company 2019s results of operations or financial position .", "a reconciliation of the beginning and ending balance of unrecognized tax benefits , excluding accrued interest recorded at march 31 , 2008 ( in thousands ) is as follows: ."], "post_text": ["the company and its subsidiaries are subject to u.s .", "federal income tax , as well as income tax of multiple state and foreign jurisdictions .", "the company has accumulated significant losses since its inception in 1981 .", "all tax years remain subject to examination by major tax jurisdictions , including the federal government and the commonwealth of massachusetts .", "however , since the company has net operating loss and tax credit carry forwards which may be utilized in future years to offset taxable income , those years may also be subject to review by relevant taxing authorities if the carry forwards are utilized .", "note 15 .", "commitments and contingencies the company 2019s acquisition of impella provides that abiomed may be required to make additional contingent payments to impella 2019s former shareholders as follows : 2022 upon fda approval of the impella 2.5 device , a payment of $ 5583333 , and 2022 upon fda approval of the impella 5.0 device , a payment of $ 5583333 if the average market price per share of abiomed 2019s common stock , as determined in accordance with the purchase agreement , as of the date of one of these milestones is achieved is $ 22 or more , no additional contingent consideration will be required with respect to that milestone .", "if the average market price is between $ 18 and $ 22 on the date of the company 2019s achievement of a milestone , the relevant milestone payment will be reduced ratably .", "these milestone payments may be made , at the company 2019s option , with cash or stock or by a combination of cash or stock , except that no more than an aggregate of approximately $ 9.4 million of these milestone payments may be made in the form of stock .", "if any of these contingent payments are made , they will result in an increase in the carrying value of goodwill .", "in june 2008 , the company received 510 ( k ) clearance of its impella 2.5 , triggering an obligation to pay $ 5.6 million of contingent payments related to the may 2005 acquisition of impella .", "these contingent payments may be made , at the company 2019s option , with cash , or stock or by a combination of cash or stock under circumstances described in the purchase agreement related to the company 2019s impella acquisition , except that approximately $ 1.8 million of the remaining $ 11.2 million potential contingent payments must be made in cash .", "it is the company 2019s intent to satisfy the impella 2.5 510 ( k ) clearance contingent payment through issuance of common shares of company stock. ."], "table": [["balance at april 1 2007", "$ 224"], ["reductions for tax positions for closing of the applicable statute of limitations", "-56 ( 56 )"], ["balance at march 31 2008", "$ 168"]], "table_ori": [["Balance at April 1, 2007", "$224"], ["Reductions for tax positions for closing of the applicable statute of limitations", "(56)"], ["Balance at March 31, 2008", "$168"]]}

Question: what is the total expected contingent payments to impella 2019s former shareholders upon fda approval of impella devices , in millions?
Evidence:
text_20: commitments and contingencies the company 2019s acquisition of impella provides that abiomed may be required to make additional contingent payments to impella 2019s former shareholders as follows : 2022 upon fda approval of the impella 2.5 device , a payment of $ 5583333 , and 2022 upon fda approval of the impella 5.0 device , a payment of $ 5583333 if the average market price per share of abiomed 2019s common stock , as determined in accordance with the purchase agreement , as of the date of one of these milestones is achieved is $ 22 or more , no additional contingent consideration will be required with respect to that milestone .
Program: add(5583333, 5583333), divide(#0, const_1000000)
Answer:
str_answer: 11.2
exe_answer: 11.16667